Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its business operations and market conditions [1] Financial Performance - The company's operating revenue for the first half of 2025 was 1.075 billion yuan, a year-on-year decrease of 15.94% [1] - The net profit attributable to shareholders was 34.0425 million yuan, down 83.12% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 63.0562 million yuan, a decrease of 68.24% year-on-year [1] - Basic earnings per share were 0.0556 yuan [1] Product Sales - Revenue from self-developed products was 872 million yuan, a year-on-year decline of 6.49% [1] - Sales volume of self-developed reagent products increased by 3.79% year-on-year [1] - Revenue from agency products was 193 million yuan, down 42.16% year-on-year [1] - Self-developed product sales accounted for 81.11% of total revenue, an increase of 8.2% [1]

招商证券股份有限公司 关于迈克生物股份有限公司 以债转股方式对全资子公司增资的核查意见 招商证券股份有限公司（以下简称"招商证券"）作为迈克生物股份有限公司 （以下简称"迈克生物"、"公司"）向特定对象发行股票的保荐机构，根据《证券 发行上市保荐业务管理办法》《上市公司募集资金监管规则》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上 市公司规范运作》及《深圳证券交易所上市公司自律监管指引第 13 号—保荐业 务》等有关规定，对公司以债转股方式（公司向特定对象发行股票募集资金形成 的对全资子公司的债权）对全资子公司增资进行了核查，具体情况如下： 一、本次增资事项概述 公司计划以债权转股权的方式对全资子公司四川迈克医疗科技有限公司（简 称"迈克医疗"）增资 100,000 万元，该债权均由公司向特定对象发行股票募集资 金形成。本次增资完成后，迈克医疗注册资本将由 15,000 万元增加至 115,000 万 元，仍为公司的全资子公司。 公司向特定对象发行股票募集资金总额扣除发行费用后，全部用于如下募集 资金投资项目： 因公司实施向特定对象发行股票投资项目"迈克生物天 ...

证券代码:300463 证券简称:迈克生物 公告编号:2025-063 迈克生物股份有限公司 关于披露 2025 年半年度报告的提示性公告 2025 年 7 月 31 日，迈克生物股份有限公司（以下简称"公司"）召开第六届董事会第五次 会议，审议通过了《关于公司 2025 年半年度报告全文及其摘要的议案》。 为使广大投资者全面了解公司的经营、财务状况，公司《2025 年半年度报告》《2025 年 半年度报告摘要》于 2025 年 8 月 1 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，敬请广大投资者注意查阅。 特此公告。 迈克生物股份有限公司 董事会 二〇二五年八月一日 第 1 页 共 1 页 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 ...

证券代码：300463 证券简称：迈克生物 公告编号：2025-069 迈克生物股份有限公司 关于以债转股方式对全资子公司增资的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 重要内容提示： 增资标的名称：公司全资子公司迈克医疗电子有限公司、四川迈克医疗科技有限公司 增资方式及金额：以债转股方式对迈克医疗电子有限公司增资 60,000 万元、对四川迈克医疗 科技有限公司增资 100,000 万元，上述债权分别为公司首次公开发行股票募集资金、向特定对 象发行股票募集资金形成。 相关风险提示：本次对全资子公司增资属于董事会决策权限范围, 无需提交公司股东大会审议 批准。本次增资事项不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组，不会对公司的财务状况和未来经营成果造成重大不利影响。 迈克生物股份有限公司（以下简称"公司"）于 2025 年 7 月 31 日召开了第六届董事会第 五次会议、第六届监事会第五次会议，会议分别审议通过了《关于以债转股方式对全资子公司 增资的议案》，同意公司以债权转股权方式对全资子公司迈克电子增资人民币 60 ...

证券代码:300463 证券简称:迈克生物 公告编号:2025-068 迈克生物股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集资金管理和使 用的监管要求》（证监会公告〔2022〕15号）、《深圳证券交易所上市公司自律监管指引第2 号—创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司自律监管指南第2号— 公告格式》的相关规定，将迈克生物股份有限公司（以下简称"公司"）2025年半年度募集资 金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发行股票注册 的批复》（证监许可〔2021〕412 号）的核准，迈克生物股份有限公司（以下简称"公司"）本 次向特定对象发行人民币普通股（A 股）56,000,000 股，每股发行价格为 28.11 元/股，募集资 金总额为人民币 1,574,160,000.00 元，扣除发行费用人 ...

迈克生物股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：唐勇 主管会计工作负责人：尹珊 会计机构负责人（会计主管人员）：游平 汇总表 第 1 页 | | | | 占用方与上市公 | 上市公司核算的 | 年期初占 | 2025 年占用累 | 年占用资 | | 年偿还累 | 2025 年上半 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | | | | 2025 | 计发生金额 | 2025 | 2025 | | 年末占用资 | 占用形成原因 | 占用性质 | | | | | 司的关联关系 | 会计科目 | 用资金余额 | （不含利息） | 金的利息(如有) | | 计发生金额 | 金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | 小计 | | - | - | - | - | - | ...

关于计提信用及资产减值准备的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）根据《企业会计准则》《深圳证券交易所上市 公司自律监管指引第2号——创业板上市公司规范运作》中关于计提资产减值准备的相关规定， 基于谨慎性原则，为真实反映公司的财务状况、资产价值及经营情况，对截至2025年6月30日 合并报表范围内可能发生信用及资产减值的有关资产计提信用及资产减值准备。根据相关规定， 本次计提减值准备无需提交公司董事会审议，现将相关情况公告如下： 一、本次计提信用及资产减值准备的范围及金额 公司 2025 年半年度对相关资产计提信用和资产减值准备 1,460.01 万元。具体如下表： 二、本次计提信用及资产减值准备的确认标准和计提方法 证券代码：300463 证券简称：迈克生物 公告编号：2025-070 迈克生物股份有限公司 （一）应收款项预期信用损失的确认标准及计提方法 第 1 页 共 5 页 单位：万元 资产类别 本期净计提金额 1、信用减值损失 788.90 其中：应收票据坏账损失 1.46 应收账款坏账损失 746 ...

迈克生物股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、监事会会议召开情况 1、迈克生物股份有限公司（以下简称"公司"）第六届监事会第五次会议通知于2025年7月 21日以邮件、短信的方式向全体监事发出并送达。 证券代码：300463 证券简称：迈克生物 公告编号：2025-067 2、本次监事会于2025年7月31日在公司会议室以现场方式召开。 3、本次会议应出席会议的监事3人，实际出席会议的监事3人。 4、本次会议由监事会主席邹媛女士召集和主持。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、法规和《迈克生物股份有限公司章程》（以下简称"《公司章程》"）的有关规 定。 二、监事会会议审议情况 经与会监事认真审议，本次会议以书面表决方式通过以下议案： （一）审议通过《关于公司2025年半年度报告全文及其摘要的议案》 经审核，监事会认为：公司董事会对《2025 年半年度报告》及其摘要的编制和审议程序符 合相关法律、法规及公司章程的规定，且 2025 年半年度报告 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) [Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, the company experienced significant declines in both operating revenue and net profit, with operating revenue decreasing by **15.94%** year-on-year and net profit attributable to shareholders plummeting by **83.12%**, or **68.24%** after deducting non-recurring gains and losses; total assets slightly increased by **0.43%** while net assets attributable to shareholders marginally decreased by **0.73%** [Key Accounting Data and Financial Indicators](index=8&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company faced significant performance pressure during the reporting period, with operating revenue at **1.075 billion CNY**, a **15.94%** year-on-year decrease, and net profit attributable to parent company shareholders at **34.04 million CNY**, a sharp **83.12%** decline; basic earnings per share were **0.0556 CNY/share**, down **83.25%**, and net cash flow from operating activities was **161.79 million CNY**, a **23.93%** decrease Key Accounting Data and Financial Indicators | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 1,075,034,096.39 | 1,278,911,868.07 | -15.94% | | Net Profit Attributable to Shareholders (CNY) | 34,042,488.83 | 201,725,714.09 | -83.12% | | Net Profit Attributable to Shareholders (Excl. Non-Recurring Items) (CNY) | 63,056,198.41 | 198,561,803.72 | -68.24% | | Net Cash Flow from Operating Activities (CNY) | 161,789,633.02 | 212,680,247.22 | -23.93% | | Basic EPS (CNY/share) | 0.0556 | 0.3320 | -83.25% | | Weighted Average ROE | 0.53% | 3.11% | -2.58% | | **Indicator** | **End of Current Period** | **End of Prior Year** | **YoY Change** | | Total Assets (CNY) | 8,010,813,632.54 | 7,976,306,737.10 | 0.43% | | Net Assets Attributable to Shareholders (CNY) | 6,322,440,254.33 | 6,369,056,728.78 | -0.73% | [Non-Recurring Gains and Losses and Amounts](index=8&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) During the reporting period, the company's total non-recurring gains and losses amounted to **-29.01 million CNY**, primarily influenced by a **10.92 million CNY** loss from fair value changes in other non-current financial assets and **27.23 million CNY** in other non-operating expenses due to tax surcharges and equipment write-offs Non-Recurring Gains and Losses (CNY) | Item | Amount (CNY) | Description | | :--- | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | 1,995,701.15 | - | | Government Grants Recognized in Current P&L | 7,195,511.01 | - | | Gains/Losses from Fair Value Changes of Financial Assets/Liabilities | -10,920,599.85 | Primarily fair value change losses on other non-current financial assets during the reporting period | | Other Non-Operating Income and Expenses | -27,228,990.61 | Primarily tax surcharges paid and equipment write-offs due to updates during the reporting period | | **Total** | **-29,013,709.58** | - | [Management Discussion and Analysis](index=10&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) [Company's Main Business, Operating Model, and Performance Drivers](index=10&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company specializes in R&D, production, sales, and service of in vitro diagnostic (IVD) products, forming a complete industry chain covering biochemical, immunoassay, and molecular diagnostics platforms; despite challenges, autonomous product revenue share increased to **81.11%** and multiple products won centralized procurement bids, laying a foundation for future growth - The company is a leading IVD enterprise in China with one of the most comprehensive product lines, covering biochemical, immunoassay, hematology, and molecular diagnostics platforms, and offering laboratory automation solutions[42](index=42&type=chunk)[50](index=50&type=chunk) - Performance decline is primarily attributed to: 1) revenue structure changes due to **divestment of agency business**; 2) intensified market competition from industry policies (e.g., centralized procurement, mutual recognition of test results) leading to both volume and price reductions; 3) a **22 million CNY** year-on-year increase in credit impairment losses; and 4) a **20 million CNY** reduction in current net profit due to **back taxes and late fees** for 2021-2023[51](index=51&type=chunk) Business Segment Performance (2025 H1) | Business Segment | 2025 H1 Revenue / Share | YoY Change | Key Driving Factors | | :--- | :--- | :--- | :--- | | **Autonomous Products** | 872 million CNY / 81.11% | Revenue -6.49%, Sales +3.79% | Instrument installations (2,409 new units/lines), centralized procurement wins driving sales growth | | **Agency Products** | 193 million CNY / 18.89% | Revenue -42.16% | Company strategically divested agency business to focus on autonomous products | | **Overseas Market** | 108 million CNY | Revenue +37.59% | Active expansion in international markets, 220 new overseas registrations | - The company's chemiluminescence (infectious diseases, sex hormones, tumor markers, etc.) and biochemical (renal function, myocardial enzymes, glucose metabolism, etc.) products were selected into Group A in provincial alliance centralized procurement in Anhui, Jiangxi, and other regions, with centralized procurement wins driving significant sales growth for related products, such as a **21.17%** year-on-year increase in tumor marker sales[54](index=54&type=chunk) [Core Competitiveness Analysis](index=18&type=section&id=%E4%BA%8C%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competitiveness lies in its comprehensive "8+1" product platform and smart laboratory solutions, sustained high R&D investment (accounting for **22.38%** of autonomous product revenue) with over **60%** core raw material self-sufficiency, an international-standard full lifecycle quality management and metrological traceability system, and a global marketing network covering **106** countries and regions providing full-cycle laboratory ecosystem empowerment services - **Product Innovation**: Established an "8+1" product platform covering biochemical, immunoassay, and hematology fields, with **519** autonomous product registrations capable of meeting **80%** of medical institutions' project needs, while also launching the Mike "Smart Lab" solution to promote laboratory automation and intelligence upgrades[60](index=60&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk) - **Technological Innovation**: Maintained high R&D investment, with **195 million CNY** invested during the reporting period, accounting for **22.38%** of autonomous product revenue, supported by **1,076** R&D personnel and achieving over **60%** core raw material self-sufficiency, ensuring independent control of key technologies[63](index=63&type=chunk)[64](index=64&type=chunk) - **Quality System**: Established a quality control system covering the entire product lifecycle, with its testing center laboratory accredited by CNAS; the company is the first Chinese enterprise representative in JCTLM, having established nearly **90** reference methods, demonstrating industry-leading metrological traceability capabilities[66](index=66&type=chunk)[67](index=67&type=chunk)[69](index=69&type=chunk) - **Global Marketing Network**: Overseas business covers **106** countries and regions, collaborating with over **400** distributors, with overseas sales revenue increasing by **37.59%** year-on-year during the reporting period; the domestic market covers over **9,400** medical institutions, with a **59%** coverage rate in tertiary hospitals[71](index=71&type=chunk)[72](index=72&type=chunk) [Main Business Analysis](index=21&type=section&id=%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) During the reporting period, the company's main business revenue was **1.075 billion CNY**, a **15.94%** year-on-year decrease, with a gross profit margin of **56.96%**, largely consistent with the prior year; the performance decline was primarily due to a **42.16%** drop in agency product revenue, while autonomous product revenue, despite a **6.49%** year-on-year decrease, maintained a high gross profit margin of **71.24%**; by region, overseas business showed strong growth, with revenue increasing by **37.59%** year-on-year and gross profit margin improving by **7.37** percentage points Main Business Performance by Category and Region | Category | Operating Revenue (CNY) | Operating Cost (CNY) | Gross Profit Margin | Revenue YoY Change | Cost YoY Change | Gross Profit Margin YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Total** | **1,075,034,096.39** | **462,706,408.47** | **56.96%** | **-15.94%** | **-15.86%** | **-0.04%** | | Autonomous Products | 871,985,074.94 | 250,802,155.93 | 71.24% | -6.49% | -2.47% | -1.18% | | Agency Products | 193,072,426.78 | 208,303,051.28 | -7.89% | -42.16% | -27.71% | -21.57% | | Southwest Region | 393,994,543.97 | 189,019,598.08 | 52.02% | -19.67% | -13.68% | -3.33% | | East China Region | 217,017,515.45 | 89,748,037.63 | 58.64% | -13.70% | -20.60% | 3.59% | | Overseas Region | 107,805,168.24 | 56,231,556.18 | 47.84% | 37.59% | 20.57% | 7.37% | [Analysis of Assets and Liabilities](index=22&type=section&id=%E4%BA%94%E3%80%81%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) As of the end of the reporting period, the company's total assets were **8.011 billion CNY**, a slight increase of **0.43%** from the beginning of the period, with changes in asset structure including a **15.53%** decrease in accounts receivable due to enhanced collection management, a **14.85%** increase in inventory due to increased finished instrument stock, and a **12.34%** increase in construction in progress due to higher investment in the IVD industrial park project; on the liability side, short-term and long-term borrowings increased by **30.04%** and **169.81%** respectively to meet project funding needs Asset and Liability Changes | Asset/Liability Item | Period-End Balance (CNY) | Change from Prior Year-End | Main Reasons for Change | | :--- | :--- | :--- | :--- | | Accounts Receivable | 1,320,355,324.96 | -15.53% | Strengthened accounts receivable management, accelerated collection | | Inventory | 1,035,486,438.13 | +14.85% | Increased finished instrument inventory to support smart laboratory promotion | | Construction in Progress | 1,239,206,813.41 | +12.34% | Increased investment in Tianfu International Bio-City IVD Industrial Park project | | Short-Term Borrowings | 331,715,986.27 | +30.04% | Increased short-term borrowings based on financing needs | | Long-Term Borrowings | 496,763,065.97 | +169.81% | Increased project loans to meet industrial park project investment | [Investment Analysis](index=24&type=section&id=%E5%85%AD%E3%80%81%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) During the reporting period, the company's total investment was **359 million CNY**, a **22.81%** year-on-year decrease, with significant non-equity investments primarily in the "Mike Bio Tianfu International Bio-City IVD Industrial Park Project," which has a total planned investment of **2.08 billion CNY** and has accumulated **1.229 billion CNY** in investment as of the end of the reporting period, reaching **59.07%** project progress; regarding raised funds, the company modified and extended some of its fundraising projects, terminating the "Instant Diagnostic Product Production Line Sub-project" and reallocating the remaining funds to the "IVD Product Technology R&D Center Sub-project" - The company's most significant investment project is the "Tianfu International Bio-City IVD Industrial Park," with **132 million CNY** invested during the reporting period and a cumulative investment of **1.229 billion CNY**, funded by raised capital, loans, and self-owned funds[87](index=87&type=chunk) - Regarding the use of raised funds, the company terminated the "Instant Diagnostic Product Production Line" sub-project due to insufficient technical and channel competitiveness, reallocating the remaining **86.91 million CNY** to the "IVD Product Technology R&D Center" sub-project[93](index=93&type=chunk)[99](index=99&type=chunk) - Due to external environmental impacts and extended equipment procurement and debugging cycles, the company repeatedly extended the completion dates for the "Tianfu International Bio-City IVD Industrial Park Project" and the "Informationization and Marketing Network Construction Project"[96](index=96&type=chunk)[97](index=97&type=chunk) [Risks and Countermeasures](index=31&type=section&id=%E5%8D%81%E3%80%81%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company faces key risks including policy changes, intensified market competition, technological innovation and leakage, talent loss, and raw material supply risks; specifically, medical reform policies like centralized procurement and DRGs/DIP payment may compress profit margins, industry competition has escalated from product upgrades to business model competition, protecting core technologies and retaining key talent are ongoing challenges for sustainable development, and reliance on imported core raw materials poses supply shortage risks; the company actively responds by closely monitoring policies, enhancing comprehensive competitiveness, improving confidentiality and incentive mechanisms, and increasing raw material self-research - **Policy Change Risk**: Policies such as centralized procurement, separation of technical services and consumables, and DRGs/DIP payments will compress corporate profit margins and accelerate industry consolidation; the company responds by closely monitoring policies and flexibly adjusting its operating strategies[108](index=108&type=chunk) - **Intensified Market Competition Risk**: Industry competition has escalated from single-product pricing to comprehensive competition in capital, product organization, and integrated service capabilities; the company enhances its competitiveness by improving product, channel, and R&D capabilities[109](index=109&type=chunk) - **Technological Innovation and Leakage Risk**: R&D innovation carries uncertainties, and most core technologies exist in non-patent forms, posing leakage risks; the company addresses this by increasing R&D investment and improving confidentiality mechanisms[111](index=111&type=chunk) - **Raw Material Supply Risk**: The domestic IVD industry's core raw materials still primarily rely on imports, facing supply shortage risks from trade frictions; the company mitigates this risk by increasing investment in raw material self-research to enhance self-sufficiency[113](index=113&type=chunk) [Corporate Governance, Environment, and Society](index=34&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) [Changes in Directors, Supervisors, and Senior Management](index=34&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, due to the company's board of directors and supervisory board re-election, some directors, supervisors, and senior management members changed, with Yang Hui, Fu Daiguo, Wang Lin, and Deng Hong leaving their original positions upon term expiration, while Deng Hong was elected as a new director, Xia Changyuan, Liu Yi, and Chen Xiaoli were elected as new independent directors or supervisors, and Lin Xin was appointed as a senior director - On January 13, 2025, due to re-election, several directors, supervisors, and senior management personnel of the company changed, including the departure of some individuals and the election and appointment of new members[120](index=120&type=chunk) [Implementation of Equity Incentive Plans](index=34&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E8%AE%A1%E5%88%92%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E6%88%96%E5%85%B6%E4%BB%96%E5%91%98%E5%B7%A5%E6%BF%80%E5%8A%B1%E6%8E%AA%E6%96%BD%E7%9A%84%E5%AE%9E%E6%96%BD%E6%83%85%E5%86%B5) The company launched a restricted stock incentive plan in 2024, but in June 2025, after deliberation by the board of directors, supervisory board, and general meeting of shareholders, it was decided to terminate the plan, consequently repurchasing and canceling the already granted first-class restricted shares and invalidating the granted second-class restricted shares - In June 2024, the company granted **7.3029 million** restricted shares to **117** incentive recipients[124](index=124&type=chunk)[125](index=125&type=chunk) - In June 2025, the company decided to terminate the 2024 restricted stock incentive plan and repurchase, cancel, and invalidate all granted restricted shares[126](index=126&type=chunk) [Social Responsibility (ESG)](index=35&type=section&id=%E4%BA%94%E3%80%81%E7%A4%BE%E4%BC%9A%E8%B4%A3%E4%BB%BB%E6%83%85%E5%86%B5) In environmental protection, the company organized the "Old Material Flow" World Earth Day event and four consecutive years of "Clean Mountain Action" parent-child environmental public welfare activities to enhance employee environmental awareness and practice green concepts; in community service, the company established the "Maidou Study Club" public welfare project, offering IVD and biomedical knowledge popularization to young people, with **202** students from multiple schools participating - **Environmental Protection**: Promoted a zero-waste lifestyle and organized employees and their families to participate in environmental practices through activities like "Old Material Flow" and "Clean Mountain Action"[127](index=127&type=chunk)[128](index=128&type=chunk) - **Community Service and Science Popularization**: Established the "Maidou Study Club" public welfare project, providing free IVD industry science education and practical platforms for young people, attracting **202** students from **5** schools[130](index=130&type=chunk) [Significant Matters](index=37&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Significant Guarantees](index=40&type=section&id=%E4%BA%8C%E3%80%81%E9%87%8D%E5%A4%A7%E6%8B%85%E4%BF%9D) As of the end of the reporting period, the company's actual total guarantees amounted to **605 million CNY**, representing **9.57%** of the company's net assets, including **342 million CNY** in external guarantees provided to distributors and **263 million CNY** in guarantees provided to its subsidiary, Mike Medical Actual Guarantee Balances (CNY) | Guarantee Type | Actual Guarantee Balance at Period-End (CNY) | | :--- | :--- | | External Guarantees (for Distributors) | 342,000,000.00 | | Guarantees for Subsidiaries (Mike Medical) | 263,070,100.00 | | **Total** | **605,070,100.00** | - The company's actual total guarantee amount accounts for **9.57%** of its net assets[150](index=150&type=chunk) [Significant Matters of Subsidiaries](index=42&type=section&id=%E5%8D%81%E5%9B%9B%E3%80%81%E5%85%AC%E5%8F%B8%E5%AD%90%E5%85%AC%E5%8F%B8%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9) During the reporting period, to advance its globalization strategy, the company established new wholly-owned subsidiaries in Thailand and Hong Kong; concurrently, to focus on core businesses and optimize channels, the company transferred its **52%** equity in controlling subsidiary Shanxi Mike and **51%** equity in Shandong Mike - **New Subsidiaries**: Established sales and service subsidiaries in Thailand and a global marketing network holding platform in Hong Kong to advance the "16+1" globalization strategy[155](index=155&type=chunk) - **Disposal of Subsidiaries**: To optimize resource allocation, the company transferred its controlling stakes in Shanxi Mike and Shandong Mike for **8.28 million CNY** and **17.41 million CNY**, respectively[156](index=156&type=chunk) [Share Changes and Shareholder Information](index=43&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) [Share Changes](index=43&type=section&id=%E4%B8%80%E3%80%81%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company's total share capital remained unchanged at **612,469,590** shares; due to changes in directors, supervisors, and senior management, restricted shares increased by **980,256** shares, with a corresponding decrease in unrestricted shares; additionally, the company completed its share repurchase plan, accumulating **3.958 million** shares at a total cost of approximately **50.02 million CNY**, later deciding to cancel these repurchased shares to reduce registered capital - Due to the re-election of directors, supervisors, and senior management, some executives resigned or were newly appointed, leading to a structural change between restricted and unrestricted shares, while the total share capital remained unchanged[159](index=159&type=chunk)[160](index=160&type=chunk) - The company completed its share repurchase plan, repurchasing a cumulative **3.958 million** shares (**0.65%** of total share capital) for a total of **50.02 million CNY**; originally intended for equity incentives, these shares were later designated for "cancellation to reduce registered capital"[161](index=161&type=chunk) [Shareholder Numbers and Shareholding](index=45&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had **34,958** common shareholders; among the top ten shareholders, the actual controllers Tang Yong, Wang Dengming, and Liu Qilin are parties acting in concert, holding a combined **23.95%** of shares; Guo Lei, holding **5.84%** of shares, is a party acting in concert with two private equity funds under Shanghai Axing Investment; some major shareholders have pledged their shares Top Shareholders and Shareholding | Shareholder Name | Shareholder Type | Shareholding Percentage | Shares Held at Period-End | Pledge Status | | :--- | :--- | :--- | :--- | :--- | | Tang Yong | Domestic Natural Person | 11.11% | 68,062,301 | Pledged 17,700,000 | | Wang Dengming | Domestic Natural Person | 7.43% | 45,534,495 | - | | Guo Lei | Overseas Natural Person | 5.84% | 35,774,906 | Pledged 22,308,000 | | Liu Qilin | Domestic Natural Person | 5.41% | 33,127,360 | - | | Chen Mei | Domestic Natural Person | 4.30% | 26,320,900 | Pledged 14,720,000 | - Tang Yong, Wang Dengming, and Liu Qilin are parties acting in concert (actual controllers) of the company; Guo Lei is a party acting in concert with funds under Shanghai Axing Investment Management Co., Ltd[166](index=166&type=chunk) [Bond-Related Information](index=49&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) The company had no bond-related matters during the reporting period - The company had no bond-related matters during this reporting period[173](index=173&type=chunk) [Financial Report](index=50&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) [Financial Statements](index=50&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This semi-annual financial report is unaudited; the consolidated balance sheet shows total assets of **8.011 billion CNY**, total liabilities of **1.639 billion CNY**, and total equity attributable to parent company shareholders of **6.322 billion CNY**; the consolidated income statement reports operating revenue of **1.075 billion CNY**, total operating costs of **1.007 billion CNY**, total profit of **28 million CNY**, net profit of **37 million CNY**, with **34 million CNY** attributable to parent company shareholders; the consolidated cash flow statement indicates net cash inflow from operating activities of **162 million CNY**, net outflow from investing activities of **321 million CNY**, net inflow from financing activities of **169 million CNY**, and cash and cash equivalents balance of **652 million CNY** at period-end Consolidated Balance Sheet Summary (June 30, 2025) | Item | Period-End Balance (CNY) | Period-Beginning Balance (CNY) | | :--- | :--- | :--- | | Total Assets | 8,010,813,632.54 | 7,976,306,737.10 | | Total Liabilities | 1,638,527,023.76 | 1,552,644,190.08 | | Total Equity Attributable to Parent Company Owners | 6,322,440,254.33 | 6,369,056,728.78 | | Total Liabilities and Owners' Equity | 8,010,813,632.54 | 7,976,306,737.10 | Consolidated Income Statement Summary (2025 Half-Year) | Item | 2025 Half-Year (CNY) | 2024 Half-Year (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 1,075,034,096.39 | 1,278,911,868.07 | | Total Operating Costs | 1,006,684,937.26 | 1,078,405,645.65 | | Total Profit | 28,409,089.61 | 223,137,098.52 | | Net Profit | 36,539,905.57 | 202,489,859.89 | | Net Profit Attributable to Parent Company Shareholders | 34,042,488.83 | 201,725,714.09 | Consolidated Cash Flow Statement Summary (2025 Half-Year) | Item | 2025 Half-Year (CNY) | 2024 Half-Year (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 161,789,633.02 | 212,680,247.22 | | Net Cash Flow from Investing Activities | -320,800,087.39 | -291,207,141.87 | | Net Cash Flow from Financing Activities | 169,425,681.25 | 196,011,670.60 | | Net Increase in Cash and Cash Equivalents | 10,938,714.29 | 117,701,765.62 |

迈克生物股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、董事会会议召开情况 1、迈克生物股份有限公司（以下简称"公司"）第六届董事会第五次会议通知于 2025 年 7 月 21 日以邮件、短信的方式向全体董事发出并送达。 2、本次会议于 2025 年 7 月 31 日在公司会议室以现场和通讯相结合的方式召开。 3、本次会议应出席会议的董事 9 人，实际出席会议的董事 9 人。 4、会议由董事长唐勇先生召集并主持，公司监事、部分高级管理人员列席了会议。 5、本次会议的召集、召开及表决程序符合《中华人民共和国公司法》（以下简称"《公司 法》"）等法律、法规、规范性文件以及《迈克生物股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，会议合法、有效。 证券代码：300463 证券简称：迈克生物 公告编号：2025-066 表决结果：9 票赞成，0 票反对，0 票弃权，0 票回避 （二）审议通过《关于公司 2025 年半年度募集资金存放与使用情况专项报告的议案》 公司严格按照《公司法》《证券法》《深圳证券交易所上 ...